Disease activity of idiopathic juvenile arthritis continues through adolescence despite the use of biologic therapies
| Autor: | Markku Korpela, Krista-Liisa Vidqvist, Merja Malin, Tuire Varjolahti-Lehtinen |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Male
Transition to Adult Care Pediatrics medicine.medical_specialty Adolescent medicine.medical_treatment Severity of Illness Index Drug Administration Schedule Arthroplasty Uveitis Young Adult Rheumatology Internal medicine Severity of illness medicine Humans Pharmacology (medical) Young adult Disease-modifying antirheumatic drug Retrospective Studies Biological Products business.industry Retrospective cohort study Temporomandibular Joint Disorders Prognosis medicine.disease Arthritis Juvenile Antirheumatic Agents Treatment Outcome Physical therapy Female business Follow-Up Studies |
| Zdroj: | Rheumatology. 52:1999-2003 |
| ISSN: | 1462-0332 1462-0324 |
| DOI: | 10.1093/rheumatology/ket256 |
| Popis: | Objectives To investigate the use of DMARDs and biologic treatments and disease activity in patients with JIA referred to the adult rheumatology clinic and to provide further information regarding the need for long-term rheumatologic care. Methods We studied the data of 154 patients retrospectively from hospital records if they met the following criteria: diagnosis of JIA and at least one visit to the adult rheumatologic unit. Previous and current antirheumatic treatment, duration of biologic therapy and disease activity were recorded. Results At the end of patient follow-up, the median age of the eligible patients was 19 years (range 16-24 years) and the disease duration was 8 years (range 0-20 years). Twenty-nine per cent of the patients were still on biologic therapies. The total median duration of treatment with at least one biologic agent was 4.2 years, and 44% of treatment durations lasted >5 years. Some disease activity was present in the last year in 58% of patients. Activity in the temporomandibular joint was detected in 14% and uveitis in 8%. Thirteen per cent did not need further specialist care and in 14% all antirheumatic medication could be tapered off. Conclusion Almost one-third of adolescents and young adults with JIA who needed specialist care were on biologics. The need for treatment in many cases is long term (>5 years). Most patients (58%) still showed evidence of mild disease activity. Adolescents and young adults with JIA are a distinct patient group in adult health care and a specialized multidisciplinary approach to treatment is needed. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|